Experimental combo targets Hard-to-Treat cancers
NCT ID NCT04375267
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal was to see if the combination is safe and to find the best dose. The idea is that olaparib may make cancer cells more sensitive to the radiation from 177Lu-DOTA-TATE, potentially killing more tumor cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-DOTA-TATE and olaparib
What this could lead to
If this works, it could point toward a more effective treatment for certain neuroendocrine tumors and other cancers that express somatostatin receptors.
What could go wrong
This is a very early Phase I trial with only 18 participants, focused on safety and dosing. It may not show significant benefit, and the combination could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dept of Oncology
Gothenburg, 41345, Sweden